Michael Brooks
President chez EDESA BIOTECH, INC.
Fortune : 74 068 $ au 31/03/2024
Profil
Michael Brooks is currently the President at Edesa Biotech, Inc. He previously worked as the Director of Business Development at Cipher Pharmaceuticals, Inc. from 2010 to 2015.
He also held positions at Edesa Biotech, Inc. (Old) and Edesa Biotech Research, Inc. In terms of education, Dr. Brooks holds an MBA from the Rotman School of Management and undergraduate and doctorate degrees from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EDESA BIOTECH, INC.
0,56% | 02/04/2024 | 17 669 ( 0,56% ) | 74 068 $ | 31/03/2024 |
Postes actifs de Michael Brooks
| Sociétés | Poste | Début |
|---|---|---|
| EDESA BIOTECH, INC. | President | 07/06/2019 |
Anciens postes connus de Michael Brooks
| Sociétés | Poste | Fin |
|---|---|---|
| CIPHER PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/01/2015 |
| Edesa Biotech Research, Inc. | Corporate Officer/Principal | - |
Edesa Biotech, Inc. (Old)
 Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Edesa Biotech, Inc. engages in the development of treatments for dermatological and anorectal diseases. Its product pipeline is based on non-steroidal molecules for the treatment of allergic contact dermatitis, hemorrhoids, and anal fissures. The company was founded by Par Nijhawan in 2015 and is headquartered in Markham, Canada. | President | - |
Formation de Michael Brooks
| Rotman School of Management | Masters Business Admin |
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CIPHER PHARMACEUTICALS INC. | Health Technology |
| EDESA BIOTECH, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Edesa Biotech, Inc. (Old)
Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Edesa Biotech, Inc. engages in the development of treatments for dermatological and anorectal diseases. Its product pipeline is based on non-steroidal molecules for the treatment of allergic contact dermatitis, hemorrhoids, and anal fissures. The company was founded by Par Nijhawan in 2015 and is headquartered in Markham, Canada. | Health Technology |
| Edesa Biotech Research, Inc. |
